Hospital
CHHP Holdings II, LLC
CHHP Holdings II, LLC was paid $17.21M by Medicaid between Jan 2018 and Dec 2024, across 203 billing codes. Its largest line is 0450, Emergency room services — 22% of everything it billed.
33Billing provider infoCHHP HOLDINGS II, LLC
HUNTINGTON PARK, CA 90255
HUNTINGTON PARK, CA 90255
33aNPI1891059127assigned 07/02/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.21M
24GClaims775,194
24DCodes billed203
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#133 of 410
Median peer was paid$6.90M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 167,758 | $3.02M | |
| 2019 | 134,441 | $4.18M | |
| 2020 | 82,400 | $1.66M | |
| 2021 | 76,485 | $1.64M | |
| 2022 | 94,670 | $2.07M | |
| 2023 | 115,922 | $2.40M | |
| 2024incomplete | 103,518 | $2.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 22% | 96,679 | 87,575 | $3.83M |
| Z7502 | 7.5% | 34,501 | 33,676 | $1.29M | |
| 70450 | Computed tomography, head or brain; without contrast material | 6.3% | 9,893 | 9,394 | $1.08M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.1% | 12,563 | 10,371 | $1.06M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.3% | 8,438 | 7,996 | $905K |
| 80053 | Comprehensive metabolic panel | 3.3% | 54,157 | 50,917 | $576K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.2% | 25,372 | 23,756 | $543K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 9,713 | 9,202 | $473K |
| 94642 | 2.3% | 3,862 | 3,596 | $389K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 54,870 | 51,439 | $389K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 14,673 | 13,967 | $344K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.8% | 4,296 | 4,064 | $309K |
191 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 4,982 | $293K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 21,207 | $269K |
| J3490 | Unclassified drugs | 1.6% | 40,480 | $269K |
| Z7610 | 1.5% | 21,022 | $265K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 7,618 | $255K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.5% | 5,202 | $253K |
| 99285 | Emergency room visit (most serious) | 1.4% | 1,400 | $246K |
| 99283 | Emergency room visit (moderate) | 1.4% | 3,933 | $241K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 1,011 | $215K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 6,966 | $208K |
| 99199 | Unlisted special service, procedure or report | 1.1% | 5,948 | $195K |
| 84484 | <1% | 19,175 | $157K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,419 | $153K |
| 83880 | <1% | 6,899 | $148K | |
| 83690 | <1% | 20,777 | $125K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,483 | $123K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,376 | $96K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,581 | $85K |
| 80305 | <1% | 8,796 | $84K | |
| 76801 | <1% | 1,764 | $82K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,349 | $80K |
| 70486 | <1% | 709 | $77K | |
| 0250 | <1% | 20,938 | $76K | |
| 0272 | <1% | 5,153 | $75K | |
| 0270 | <1% | 16,593 | $70K | |
| 90715 | <1% | 2,243 | $70K | |
| 0636 | <1% | 5,253 | $64K | |
| 87040 | <1% | 3,632 | $56K | |
| 81001 | <1% | 18,485 | $56K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,913 | $51K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,738 | $50K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 810 | $48K |
| 81025 | <1% | 9,996 | $46K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,534 | $46K |
| 83605 | <1% | 4,739 | $42K | |
| 72100 | <1% | 1,667 | $40K | |
| 73562 | <1% | 1,893 | $39K | |
| 73130 | <1% | 1,805 | $39K | |
| 84703 | <1% | 6,064 | $39K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,351 | $37K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,937 | $35K |
| 73630 | <1% | 1,704 | $35K | |
| 76830 | Ultrasound, transvaginal | <1% | 685 | $35K |
| 73610 | <1% | 1,539 | $34K | |
| 85730 | <1% | 6,971 | $33K | |
| 93970 | <1% | 224 | $33K | |
| 81003 | <1% | 15,272 | $32K | |
| 96368 | <1% | 1,597 | $31K | |
| 0206 | <1% | 13 | $30K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 470 | $29K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,342 | $29K |
| 84702 | <1% | 2,399 | $29K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 850 | $26K |
| 0762 | <1% | 145 | $26K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 462 | $26K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,367 | $25K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,654 | $25K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,081 | $24K |
| 85610 | <1% | 7,638 | $24K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,068 | $24K |
| 82948 | <1% | 5,607 | $23K | |
| 74018 | <1% | 1,389 | $22K | |
| 80320 | <1% | 4,222 | $21K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,961 | $21K |
| 87430 | <1% | 2,535 | $20K | |
| 0360 | <1% | 171 | $19K | |
| 87186 | <1% | 2,587 | $18K | |
| A4649 | Surgical supply; miscellaneous | <1% | 4,124 | $17K |
| 73110 | <1% | 740 | $17K | |
| 94760 | <1% | 831 | $15K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 202 | $14K |
| 87077 | <1% | 2,575 | $13K | |
| 83735 | <1% | 163 | $13K | |
| 87807 | <1% | 1,913 | $12K | |
| 73030 | <1% | 580 | $11K | |
| Z7500 | <1% | 328 | $11K | |
| 72131 | <1% | 115 | $11K | |
| 81002 | <1% | 1,870 | $11K | |
| 73020 | <1% | 784 | $11K | |
| 86328 | <1% | 335 | $10K | |
| 74022 | <1% | 297 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 88 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 779 | $9K |
| 85007 | <1% | 3,269 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,323 | $9K |
| 0271 | <1% | 617 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 357 | $8K |
| 29125 | <1% | 247 | $8K | |
| 12001 | <1% | 408 | $8K | |
| 85027 | <1% | 1,592 | $7K | |
| 0761 | <1% | 296 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 560 | $7K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 240 | $6K |
| 80329 | <1% | 1,691 | $6K | |
| 87400 | <1% | 1,420 | $6K | |
| 86901 | <1% | 2,164 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 143 | $5K |
| 73090 | <1% | 370 | $5K | |
| 86769 | <1% | 173 | $5K | |
| 85379 | <1% | 789 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,116 | $5K |
| 73502 | <1% | 212 | $5K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 836 | $5K |
| 73600 | <1% | 304 | $5K | |
| 0710 | <1% | 214 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 496 | $5K |
| 73590 | <1% | 306 | $4K | |
| 93971 | <1% | 53 | $4K | |
| 0760 | <1% | 193 | $4K | |
| 73564 | <1% | 209 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 932 | $4K |
| 73080 | <1% | 184 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 162 | $4K |
| 76870 | <1% | 69 | $4K | |
| 72050 | <1% | 134 | $4K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 60 | $3K |
| 82010 | <1% | 583 | $3K | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 71 | $3K |
| 86900 | <1% | 935 | $3K | |
| 29515 | <1% | 45 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 230 | $2K |
| 73060 | <1% | 48 | $2K | |
| 71020 | <1% | 86 | $2K | |
| 70496 | <1% | 14 | $2K | |
| 96376 | <1% | 229 | $2K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 53 | $2K |
| 82140 | <1% | 236 | $2K | |
| 86850 | <1% | 484 | $2K | |
| 73120 | <1% | 151 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 15 | $2K |
| 94799 | <1% | 138 | $2K | |
| 70498 | <1% | 15 | $2K | |
| 71010 | <1% | 105 | $2K | |
| 87420 | <1% | 497 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 386 | $1K |
| 10060 | <1% | 84 | $1K | |
| 73140 | <1% | 107 | $1K | |
| 73620 | <1% | 98 | $1K | |
| 12002 | <1% | 83 | $1K | |
| 0451 | <1% | 62 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 256 | $1K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 207 | $1K |
| 12011 | <1% | 39 | $1K | |
| 0324 | <1% | 85 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 114 | $762.66 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 135 | $754.34 |
| 73552 | <1% | 55 | $713.40 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 219 | $693.18 |
| 80047 | <1% | 48 | $662.20 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 33 | $500.81 |
| 82728 | <1% | 56 | $499.43 | |
| 99221 | <1% | 18 | $477.40 | |
| E0116 | Crutch, underarm, other than wood, adjustable or fixed, with pad, tip, handgrip, with or without shock absorber, each | <1% | 47 | $458.69 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $455.70 |
| G0378 | Hospital observation service, per hour | <1% | 18 | $445.95 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 99 | $426.13 |
| 83615 | <1% | 83 | $404.31 | |
| 82803 | <1% | 30 | $370.67 | |
| 88312 | <1% | 26 | $368.69 | |
| 80061 | Lipid panel | <1% | 40 | $310.03 |
| J7999 | Compounded drug, not otherwise classified | <1% | 47 | $280.16 |
| 71101 | <1% | 13 | $246.19 | |
| 82550 | <1% | 79 | $235.65 | |
| 99070 | <1% | 153 | $224.32 | |
| 73560 | <1% | 12 | $205.61 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 17 | $161.46 |
| 0300 | <1% | 117 | $149.51 | |
| 73100 | <1% | 13 | $140.46 | |
| 70360 | <1% | 12 | $134.61 | |
| 72040 | <1% | 12 | $125.85 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 26 | $122.79 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 28 | $118.53 |
| 99406 | <1% | 12 | $114.51 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 17 | $113.97 |
| A6216 | Gauze, non-impregnated, non-sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 53 | $108.60 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 17 | $92.65 |
| 80076 | <1% | 15 | $68.89 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 13 | $67.95 |
| A6451 | Moderate compression bandage, elastic, knitted/woven, load resistance of 1.25 to 1.34 foot pounds at 50% maximum stretch, width greater than or equal to three inches and less than five inches, per yard | <1% | 95 | $45.60 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 54 | $44.03 |
| 84100 | <1% | 14 | $43.93 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 28 | $40.17 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 12 | $30.09 |
| 87210 | <1% | 13 | $28.62 | |
| 85651 | <1% | 12 | $25.96 | |
| A6220 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 13 | $11.55 |
| A6446 | Conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard | 0% | 14 | $0.00 |
| 80354 | 0% | 67 | $0.00 | |
| 0730 | 0% | 12 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 97 | $0.00 |
| 0301 | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMACPHERSON, JAMES (MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Gardena Hospital LP | Gardena, CA | $15.36M |
| Eladh, LP | Los Angeles, CA | $5.38M |
| CPH Hospital Management LLC | Norwalk, CA | $3.68M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.